Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Protective effects of immunization with a novel 4 recombinant pore-forming toxoid combination vaccine in a rabbit model of systemic methicillin-resistant Staphylococcus aureus infection

  • Received : 2024.09.06
  • Accepted : 2024.09.21
  • Published : 2024.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Staphylococcus aureus is a Gram-positive bacterium that most frequently acquires antibiotic resistance. As an opportunistic pathogen, it can cause conditions such as bacteremia, sepsis, and myocarditis. Due to the social need for a vaccine against methicillin-resistant Staphylococcus aureus (MRSA), many research groups have been designing and studying vaccines for decades. In this study, we developed a multivalent vaccine and evaluated its efficacy by applying a novel adjuvant, β-glucan. Materials and Methods: A vaccine composed of four pore-forming toxins from S. aureus was administered to rabbits 3 times, after which they were challenged with S. aureus USA 300 LAC strain. We measured changes in the rabbits' body weight to monitor systemic adverse reactions and analyzed the total immunoglobulin G antibody titer against the four antigens using enzyme-linked immunosorbent assay. For each rabbit, the number of abscesses and colony-forming units (CFU) in the kidneys were measured. Results: In all vaccinated groups, strong antibody responses against the four antigens were observed. After challenging with MRSA, the vaccinated groups showed less weight change compared to the non-vaccinated groups (average 5.7% versus 13.5%). Additionally, the number of renal abscesses was significantly lower in the vaccinated groups, with three individuals in group 1 (four antigens adjuvanted with β-glucan_PK1) showing no abscess formation. The number of bacteria identified in the kidneys was also statistically significantly lower in the vaccinated group compared to the non-vaccinated group. Conclusion: We demonstrated that the four toxoid antigens we selected can protect against S. aureus infection in a rabbit model and that β-glucan could be used as an immune enhancer. Overall, our study shows that new antigen combinations can induce protective immunity in animal models and that a toxin-based vaccine can help control bacterial colonization.

Keywords

Acknowledgement

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: RS-2023-KH140377[HV23C0112]).

References

  1. Lam JC, Gregson DB, Robinson S, Somayaji R, Conly JM, Parkins MD. Epidemiology and outcome determinants of Staphylococcus aureus bacteremia revisited: a population-based study. Infection 2019;47:961-71.
  2. Miller LS, Fowler VG, Shukla SK, Rose WE, Proctor RA. Development of a vaccine against Staphylococcus aureus invasive infections: evidence based on human immunity, genetics and bacterial evasion mechanisms. FEMS Microbiol Rev 2020;44:123-53.
  3. Gasch O, Ayats J, Angeles Dominguez M, et al. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: secular trends over 19 years at a university hospital. Medicine (Baltimore) 2011;90:319-27.
  4. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009;7:629-41.
  5. McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med 2017; 90:269-81.
  6. Kim T, Chong YP, Park KH, et al. Clinical and microbiological factors associated with early patient mortality from methicillin-resistant Staphylococcus aureus bacteremia. Korean J Intern Med 2019;34:184-94.
  7. Spaan AN, van Strijp JA, Torres VJ. Leukocidins: staphylococcal bi-component pore-forming toxins find their receptors. Nat Rev Microbiol 2017;15:435-47.
  8. Seilie ES, Bubeck Wardenburg J. Staphylococcus aureus pore-forming toxins: the interface of pathogen and host complexity. Semin Cell Dev Biol 2017;72:101-16.
  9. Mao X, Kim J, Zhang Q, et al. The N2N3 domains of ClfA, FnbpA and FnbpB in Staphylococcus aureus bind to human complement factor H, and their antibodies enhance the bactericidal capability of human blood. J Biochem 2021;169:543-53.
  10. Teymournejad O, Li Z, Beesetty P, Yang C, Montgomery CP. Toxin expression during Staphylococcus aureus infection imprints host immunity to inhibit vaccine efficacy. NPJ Vaccines 2023;8:3.
  11. Caldera JR, Tsai CM, Trieu D, et al. The characteristics of pre-existing humoral imprint determine efficacy of S. aureus vaccines and support alternative vaccine approaches. Cell Rep Med 2024;5:101360.
  12. Clegg J, Soldaini E, McLoughlin RM, Rittenhouse S, Bagnoli F, Phogat S. Staphylococcus aureus vaccine research and development: the past, present and future, including novel therapeutic strategies. Front Immunol 2021;12:705360.
  13. Zhang Q, Jiang T, Mao X, et al. Development of combination vaccine conferring optimal protection against six pore-forming toxins of Staphylococcus aureus. Infect Immun 2021;89:e0034221.
  14. Burlak C, Hammer CH, Robinson MA, et al. Global analysis of community-associated methicillin-resistant Staphylococcus aureus exoproteins reveals molecules produced in vitro and during infection. Cell Microbiol 2007;9:1172-90.
  15. Fraunholz M, Sinha B. Intracellular Staphylococcus aureus: live-in and let die. Front Cell Infect Microbiol 2012;2:43.
  16. Saito S, Quadery AF. Staphylococcus aureus lipoprotein induces skin inflammation, accompanied with IFN-γ-producing T cell accumulation through dermal dendritic cells. Pathogens 2018;7:64.
  17. Ferraro A, Buonocore SM, Auquier P, et al. Role and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus. Hum Vaccin Immunother 2019;15:2980-92.
  18. Pozzi C, Olaniyi R, Liljeroos L, Galgani I, Rappuoli R, Bagnoli F. Vaccines for Staphylococcus aureus and target populations. Curr Top Microbiol Immunol 2017;409:491-528.
  19. Le VT, Tkaczyk C, Chau S, et al. Critical role of alpha-toxin and protective effects of its neutralization by a human antibody in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2016;60:5640-8.
  20. Diep BA, Le VT, Visram ZC, et al. Improved protection in a rabbit model of community-associated methicillin-resistant Staphylococcus aureus necrotizing pneumonia upon neutralization of leukocidins in addition to alpha-hemolysin. Antimicrob Agents Chemother 2016;60:6333-40.
  21. Scherr TD, Hanke ML, Huang O, et al. Staphylococcus aureus biofilms induce macrophage dysfunction through leukocidin AB and alpha-toxin. mBio 2015;6:e01021-15.
  22. Venkatasubramaniam A, Kanipakala T, Ganjbaksh N, et al. A critical role for HlgA in Staphylococcus aureus pathogenesis revealed by A switch in the SaeRS two-component regulatory system. Toxins (Basel) 2018;10:377.
  23. Jing XQ, Cao DY, Liu H, Wang XY, Zhao XD, Chen DK. Pivotal role of IL-17-producing γδ T cells in mouse chronic mastitis experimentally induced with Staphylococcus aureus. Asian J Anim Vet Adv 2012;7:1266-78.
  24. Dillen CA, Pinsker BL, Marusina AI, et al. Clonally expanded γδ T cells protect against Staphylococcus aureus skin reinfection. J Clin Invest 2018;128:1026-42.
  25. Cho JS, Pietras EM, Garcia NC, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 2010;120:1762-73.
  26. Cheng P, Liu T, Zhou WY, et al. Role of gamma-delta T cells in host response against Staphylococcus aureus-induced pneumonia. BMC Immunol 2012;13:38.
  27. Murphy AG, O'Keeffe KM, Lalor SJ, Maher BM, Mills KH, McLoughlin RM. Staphylococcus aureus infection of mice expands a population of memory γδ T cells that are protective against subsequent infection. J Immunol 2014;192:3697-708.
  28. Zhang H, Pan N, Ma C, et al. Vaccine composition formulated with a novel Lactobacillus-derived exopolysaccharides adjuvant provided high protection against Staphylococcus aureus. Vaccines (Basel) 2021;9:775.
  29. Pan W, Hao S, Zheng M, et al. Oat-derived β-glucans induced trained immunity through metabolic reprogramming. Inflammation 2020;43:1323-36.
  30. Goodridge HS, Wolf AJ, Underhill DM. Beta-glucan recognition by the innate immune system. Immunol Rev 2009;230:38-50.
  31. Vetvicka V, Vannucci L, Sima P. β-glucan as a new tool in vaccine development. Scand J Immunol 2020;91:e12833.